Dividend Comparison Reinforces Income Appeal, But Medtronic's Overhang Keeps Rating at WAIT

What happened

A 24/7 Wall Street article frames Medtronic and Abbott as nearly half-century dividend growers, suggesting income investors face a forced choice between the two. The piece appears amid Medtronic's strong cardiovascular momentum, including a +80% worldwide ablation growth, but also after an adverse $382 million jury verdict with automatic trebling and injunction risk. The latest DeepValue master report already rates Medtronic a WAIT, citing a rich valuation at 26.6x earnings and 16.2x EV/EBITDA that leaves little room for operational disappointment. While the dividend record is a point in Medtronic's favor, the report's downside scenarios center on Abbott's Volt PFA commercialization and legal cash outflows, which could pressure the payout over time despite current free cash flow strength. No new operational or financial disclosures accompanied the article, so it adds no incremental evidence on the key catalysts: FY26 Q4 results in May, PFA share durability, and Applied litigation posture.

Implication

The article may tempt dividend-focused investors to overweight Medtronic for its reliability, but the current valuation already prices a sustained cardiovascular re-acceleration. The Applied litigation verdict, with automatic trebling and possible injunction, creates a cash flow and headline risk that could stretch the dividend coverage if it goes against the company. Abbott's Volt approval raises the probability of PFA pricing concessions that would pressure margins and potentially slow Medtronic's share gains. A more prudent approach is to wait for Medtronic's FY26 Q4 report in May to see whether ablation growth remains robust and management addresses litigation timelines, or for the stock to pull back toward the $90 attractive entry level. Until then, the risk-reward is not compelling enough to buy solely on dividend legacy.

Thesis delta

No material change to the fundamental thesis. The article reinforces that Medtronic's dividend history is a stability factor, but the current valuation and litigation overhang still require proof of PFA durability and legal clarity before adding. The wait-for-better-entry stance remains in force, with the $90 attractive entry still preferred over the current $95.60.